Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James Gern
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
3V Biosciences
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
NA
Infant specific-IgE, rhinovirus-C bronchiolitis, and incident asthma in MARC-35
In a 17-center prospective cohort study of ~940 infants originally hospitalized with bronchiolitis, who are being followed until the age of 3 years, investigators propose to add an in-person evaluation at age 3.5 years and to extend follow-up to age 5 years. These important changes will permit investigation, in a diverse U.S. cohort (~52% African-American or Hispanic), of the relation between two infant factors (specific IgE and rhinovirus type C bronchiolitis) and the development of asthma. The study is sufficiently large that it can test the hypothesis that infants with both risk factors (as compared to infants with neither) are at much higher risk of developing childhood asthma, a new finding that will advance efforts to prevent childhood asthma.
Filed on March 27, 2015.
Tell us what you know about James Gern's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “James Gern”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | Value cannot be readily determined |
| James Gern | University of Wisconsin Madison | Conflict of Interest | 3V Biosciences | $0 - $4,999 |
| James Gern | University of Wisconsin Madison | Conflict of Interest | 3V Biosciences | Value cannot be readily determined |
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | $5,000 - $9,999 |
| James Gern | University of Wisconsin Madison | Conflict of Interest | 3V Biosciences | Value cannot be readily determined |
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | $5,000 - $9,999 |
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | Value cannot be readily determined |
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | $5,000 - $9,999 |
| James Gern | University of Wisconsin Madison | Conflict of Interest | Meissa Vaccines | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.